Omega Therapeutics, Inc. (OMGA)
- Previous Close
2.3800 - Open
2.3900 - Bid 2.4000 x 400
- Ask 2.4300 x 200
- Day's Range
2.3500 - 2.4900 - 52 Week Range
1.3000 - 10.0900 - Volume
272,038 - Avg. Volume
366,617 - Market Cap (intraday)
132.924M - Beta (5Y Monthly) 1.99
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6600 - Earnings Date May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
omegatherapeutics.comRecent News: OMGA
Performance Overview: OMGA
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OMGA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OMGA
Valuation Measures
Market Cap
132.92M
Enterprise Value
200.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
26.91
Price/Book (mrq)
3.21
Enterprise Value/Revenue
40.60
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.89%
Return on Equity (ttm)
-112.29%
Revenue (ttm)
4.94M
Net Income Avi to Common (ttm)
-92.28M
Diluted EPS (ttm)
-1.6600
Balance Sheet and Cash Flow
Total Cash (mrq)
60.03M
Total Debt/Equity (mrq)
308.59%
Levered Free Cash Flow (ttm)
-47.34M
Research Analysis: OMGA
Company Insights: OMGA
OMGA does not have Company Insights